zolpidem

(redirected from Sublinox)
Also found in: Dictionary.

zolpidem

 [zōl-pi´dem]
a non-benzodiazepinesedative and hypnotic used orally as the tartrate salt in the short-term treatment of insomnia.

zol·pi·dem

(zol'pi-dĕm),
A sedative/hypnotic drug useful for treating anxiety and resembling benzodiazepines in its pharmacology but differing somewhat in chemical structure. Unlike benzodiazepines, zolpidem lacks prominent anticonvulsant properties, and less tolerance may develop with its use.

zolpidem

(zōl′pə-dĕm′)
n.
A non-benzodiazepine sleep-inducing drug, C19H21N3O, used in its tartrate form to treat insomnia.

zolpidem

An imidazopyridine HYPNOTIC drug used for the short-term treatment of INSOMNIA. A brand name is Stilnoct.

zol·pi·dem

(zol'pi-dĕm)
A sedative/hypnotic drug useful for treating anxiety and resembling benzodiazepines in its pharmacology but differing somewhat in chemical structure. Unlike benzodiazepines, zolpidem lacks prominent anticonvulsant properties, and less tolerance may develop with its use.
References in periodicals archive ?
Meda, which holds the global marketing rights to Sublinox, has been selling the product in the USA since 2009.
Sublinox, a rapidly dissolving sublingual tablet with zolpidem as active ingredient, is indicated for the treatment of short-term insomnia.
Sublinox (OX 22) is based on the well-documented substance zolpidem using Orexo's sublingual technology, involving a tablet placed under the tongue for fast and effective uptake of the active substance over the sublingual mucosa.
"The study confirms previous results and shows that Sublinox (OX 22), in addition to fast sleep induction, offers patients with sleeping disturbances good and maintained sleep without 'day-after'- residual effects.
Orexo initiates Phase III studies during 2006 to further document Sublinox (OX 22) unique clinical profile in preparation for registration and out-licensing.
Sublinox (OX 22), a drug for the treatment of temporary insomnia, helps the patient fall asleep quickly and remain asleep throughout the night.
Swedish speciality pharma companies Orexo AB (OMX Stockholm:ORX) and Meda AB (OMX Stockholm:MEDA A) announced on Monday (14 April) a major agreement under which Meda acquires the global commercialisation rights to Orexo's patented insomnia treatment drug Sublinox and the patented antihistamine nasal spray formulation OX-NLA.
We believe Meda is going to be an excellent marketing partner for Sublinox and OX-NLA with their pan-European and US presence," said Torbjorn Bjerke, president and CEO of Orexo.
We strengthen Meda's pipeline and add another significant marketing opportunity in the US in the near term with Sublinox," added Anders Lonner, CEO of Meda.